The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer. 

https://www.bms.com/healthcare-providers/time-back-campaign-honoring-oncologists-in-cancer-care.html

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

ASCENT-04 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2508959

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2511734

Pfizer and the American Cancer Society are teaming up through Change the Odds to help break barriers in cancer care disparities with a focus on: Cancer Screening, Patient Resources & support, and Clinical Trials. Learn more below.

This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. 

The Carolinas Bladder Cancer Collaboration is a grassroots initiative between Pfizer and passionate healthcare professionals across the Carolinas. Our goal is to improve guideline concordant care and therapy management in la/mUC. This collaboration involves 24 healthcare professionals across 7 healthcare systems, including 4 NCI Centers.

Please see the attached PDF of the Pfizer sponsored Advisory Board Resource titled "Five Ways to Improve Bladder Cancer Care." This resource shares key insights learned from the research team's comprehensive literature review and interviews. Each strategy is supported by evidence, additional resources, and guidance to help improve the quality of care for bladder cancer programs.

For additional resources and information on joining the collaboration, please reach out to 

A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit 

 or download the resource below to learn more.

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3

In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.

Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.

To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.

Published on: February 17, 2025

Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

Consider updating your billing software to reflect the permanent J-code for RYTELO, J0870, and units: 1 unit per 1 mg, so J-code can be used on or after January 1, 2025.



Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).


Hosted by Dr Javier Cortés and Prof. Peter Schmid, joined by an international panel of experts in ADCs and breast cancer, this educational podcast series unveils invaluable insights into ADCs, shedding light on their developmental history, their distinctive structural features and mechanisms of action, as well as potential future advancements.

Too often, women with endometrial cancer (EC) have reported that their symptoms were stigmatized and dismissed. Even though diagnoses and deaths from this type of uterine cancer are on the rise, EC remains under-recognized.

Spot Her® is an initiative to help end the silence around EC and empower all people across generations and cultures to speak up, take action, and spot the potential signs at an early stage—when EC may be more treatable.





This resource is intended for patients looking to:

Understand what Ocular AEs may occur while on ELAHERE

Review the important steps involved in proactively managing eye care while on treatment

Learn the importance of communicating any side effects to your care team




This resource is intended for eye doctors or oncologists looking to:

Understand why patients on ELAHERE require eye exams, and when

Learn about what ocular AEs may be experienced by patients on ELAHERE

Review the proactive eye drops administration patients should take during treatment

See resources available to help facilitate communication between eye doctors and oncologists

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

 and share this site with your patients.






Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at 

 is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

Learn more about this hematologic disease at 

To improve outcomes for patients with acute myeloid leukemia, especially those who do not receive a transplant, the Association of Cancer Care Centers (ACCC), with support from 

, has partnered with the HealthTree Foundation for Acute Myeloid Leukemia to develop a 

This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from 

 to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:

Educational Resources

Educational Resources

Bristol Myers Squibb’s Time Back campaign honors the most precious gift oncologists provide in cancer care: time

View these recent articles in the New England Journal of Medicine from our member

Change the Odds: Uniting to Improve Cancer Outcomes™

Explore Two New Publications on Real-World-Evidence in ESR1-mutated Metastatic Breast Cancer

2026 Regeneron The Different Colors of Skin Cancer Brochure

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Five Ways to Improve Bladder Cancer Care

Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma

Help patients explore everything CAR T Cell Therapy